Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $922
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice TargetHot
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $875 to $922.
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $875 to $922.